ADAMTS13 mutational analysis in Chinese patients with chronic relapsing thrombotic thrombocytopenic purpura

Hong Kong Journal of Paediatrics

Volumn 11, Issue 1, 2006, Pages 22-27

  Ma, E S K ^a   Li, Y H ^a   Kwok, J S Y ^a   Ling, S C ^b   Yau, P W ^c   Chan, G C F ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

ADAMTS13; Mutation; Thrombotic thrombocytopenic purpura; vWF cleaving protease

Indexed keywords

NEUTRALIZING ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADAMTS13 GENE; ANTIBODY TITER; ARTICLE; CASE REPORT; CHINESE; CHRONIC DISEASE; DISEASE SEVERITY; FEMALE; FRANCE; GENE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; PRESCHOOL CHILD; PREVALENCE; RELAPSE; RISK FACTOR; SCHOOL CHILD; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 31344462630     PISSN: 10139923     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-94.
2. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005;106:11-7.
3. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002;99:11902-7.
4. Antoine G, Zimmermann K, Plaimauer B, et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol 2003;120:821-4.
5. Assink K, Schiphorst R, Allford S, et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003;63:1995-9.
6. Savasan S, Lee SK, Ginsburg D, Tsai HM. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood 2003;101:4449-51.
7. Schneppenheim R, Budde U, Oyen F, et al. von Willebrand factor cleaving protease and ADAMTSl3 mutations in childhood TTP. Blood 2003;101:1845-50.
8. Matsumoto M, Kokame K, Soejima K, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004;103:1305-10.
9. Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 2004;103:627-9.
10. Uchida T, Wada H, Mizutani M, et al. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 2004;104:2081-3.
11. Veyradier A, Lavergne JM, Ribba AS, et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2004;2:424-9.
12. Licht C, Stapenhorst L, Simon T, Budde U, Schneppenheim R, Hoppe B. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney Int 2004;66:955-8.
13. Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP) Thromb Haemost 1999;82:1386-9.
14. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002;100:710-3.
15. Scheiflinger F, Knobl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003;102:3241-3.
16. Gao WQ, Wang ZY, Bai X, Ruan C. The frequency of P475S polymorphism in von Willebrand factor-cleaving protease among Chinese population and its relevance to arterial thrombotic disorders. J Thromb Haemost 2003;1 (suppl 1):P0376.